Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 4/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3441298 | 0.90 | HSP90AB1 (0.49) | FBP1ADORA1TLR7DHFRCYP2D6 | |
| SCHEMBL3441461 | 0.87 | CYP2D6 (0.43) | FBP1ADORA2AADORA1TLR7DHFR | |
| SCHEMBL3441092 | 0.85 | TLR7 (0.43) | ADORA2AADORA1TLR7DHFRKDM4E | |
| SCHEMBL3441043 | 0.85 | HSP90AA1 (0.50) | ADORA2AADORA1TLR7ALDH1A1TMIGD3 | |
| SCHEMBL3441218 | 0.84 | HSP90AA1 (0.49) | ADORA2AADORA1TLR7ALDH1A1TMIGD3 | |
| SCHEMBL3441083 | 0.82 | RXFP1 (0.45) | ADORA2AADORA1TLR7DHFRCYP2D6 | |
| SCHEMBL3441078 | 0.82 | MEN1 (0.46) | ADORA2AADORA1TLR7DHFRCYP2D6 | |
| SCHEMBL3441222 | 0.82 | ALDH1A1 (0.46) | ADORA2AADORA1TLR7KDM4EALDH1A1 | |
| SCHEMBL3441254 | 0.82 | TLR7 (0.41) | TLR7DHFRCYP2D6KDM4EALDH1A1 | |
| SCHEMBL3454621 | 0.81 | SIGMAR1 (0.44) | FBP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200615-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | Gilead Palo Alto, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009052310-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099212-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | ZABLOCKI JEFF | 2009-04-16 | — | — | US | disclosed |
| US-7238700-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1401837-B1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040209899-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (IN) | 2004-10-21 | — | — | US | disclosed |
| US-6770651-B2 | THERAPY FOR ASTHMA, DIARRHEA | PALLE VENKATA (US) | 2004-08-03 | — | — | US | disclosed |
| EP-1401837-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030064999-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (US) | 2003-04-03 | — | — | US | disclosed |
| WO-2003006465-A1 | PARTIAL AND FULL AGONIST OF A ADENOSINE RECEPTORS | CV THERAPEUTICS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003002566-A1 | PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064999-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | FBP1 2204/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20090099212-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | ADORA3, ADORA2A, ADORA2B | FBP1 3198/4885ADORA2A 2/4885ADORA1 4/4885 |
| US-20040209899-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | FBP1 1935/4885ADORA2A 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.